Chronic obstructive pulmonary disease

BioInnovation Institute Creation House program announces intake of four innovative early stage start-up companies

Thursday, September 23, 2021 - 8:00am

COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.
  • "BII's Creation House program is designed to support start-ups in their journey, and essentially increase the likelihood of success.
  • Creation House is for companies with a solid, initial business plan.
  • Its diverse team brings venture capital, pharma and business expertise together to help early stage companies accelerate to the next level.

BioInnovation Institute Creation House program announces intake of four innovative early stage start-up companies

Thursday, September 23, 2021 - 8:00am

COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ -- BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program. Creation House consists of a founder-friendly convertible loan of DKK 10M and 18 months incubation at BII with access to labs and office space, business development support, and BII partners. The program allows participants to meet and interact with BII's network of investors, industry partners, alumni and fellow entrepreneurs across its other programs, and is specifically designed to guide companies to a competitive international level and prepare teams for discussions with investors ahead of series A financing rounds.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.
  • "BII's Creation House program is designed to support start-ups in their journey, and essentially increase the likelihood of success.
  • Creation House is for companies with a solid, initial business plan.
  • Its diverse team brings venture capital, pharma and business expertise together to help early stage companies accelerate to the next level.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets - ResearchAndMarkets.com

Wednesday, September 22, 2021 - 5:11pm

The "Global Obstructive Lung Disease Management Research Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Obstructive Lung Disease Management Research Report" report has been added to ResearchAndMarkets.com's offering.
  • The report provides a glimpse into the near future of respiratory disease treatment by highlighting newer therapeutics and advanced technologies that can address existing challenges in obstructive lung disease management.
  • Obstructive lung diseases such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis are a huge burden on the global healthcare system.
  • What are the growth opportunities for companies developing new therapeutics and technologies for obstructive lung disease management?

Pulmonx Announces Two Additional Significant Blue Cross Blue Shield Plans Now Provide Coverage for Severe Emphysema/COPD Treatment

Tuesday, September 21, 2021 - 9:05pm

This follows similar coverage decisions by other BCBS plans and now establishes positive coverage with the majority of BCBS covered members in the US (for an aggregate of 69 million covered lives).

Key Points: 
  • This follows similar coverage decisions by other BCBS plans and now establishes positive coverage with the majority of BCBS covered members in the US (for an aggregate of 69 million covered lives).
  • The Zephyr Valves are placed by bronchoscopy and are the first minimally invasive treatment option for patients who remain symptomatic despite medication and oxygen therapies.
  • The Zephyr Valve is a minimally invasive treatment option for severe COPD/emphysema, a chronic, progressive, and irreversible lung disease characterized by the destruction of lung tissue.
  • Pulmonx Corporation (NASDAQ: LUNG) is a global leader in minimally invasive treatments for severe lung disease.

Renovion and the COPD Foundation Launch COPD and Bronchiectasis Development Partnership to Address Unmet Patient Need

Tuesday, September 21, 2021 - 3:19pm

Together, Renovion and the COPD Foundation are leveraging the foundational research in bronchiectasis registries and COPD studies, such as those utilizing the SPIROMICS and COPDGene groups that demonstrate a need for therapies that target airway mucus plugging.

Key Points: 
  • Together, Renovion and the COPD Foundation are leveraging the foundational research in bronchiectasis registries and COPD studies, such as those utilizing the SPIROMICS and COPDGene groups that demonstrate a need for therapies that target airway mucus plugging.
  • The unique collaborative approach of the COPD Foundations global partnerships and COPD360Net allows for patient-centered drug development to accelerate clinical programs.
  • Finding the right patient target for clinical trials is a primary challenge of drug development today and this is especially true in the COPD and bronchiectasis patient populations.
  • It aims to accelerate the development of a therapeutic COPD360Net pipeline asset that may benefit individuals with COPD and / or bronchiectasis.

Kinaset Therapeutics Announces Dosing Underway in its Phase 1b Study of KN-002 in Healthy Volunteers and Asthma Patients

Wednesday, September 15, 2021 - 3:00pm

Kinaset Therapeutics , a biopharmaceutical company developing a next generation anti-inflammatory therapy to treat patients with severe asthma, today announced that the first 24 participants have been dosed in its Phase 1b placebo-controlled study.

Key Points: 
  • Kinaset Therapeutics , a biopharmaceutical company developing a next generation anti-inflammatory therapy to treat patients with severe asthma, today announced that the first 24 participants have been dosed in its Phase 1b placebo-controlled study.
  • This Phase 1b clinical study is an important step in our goal to develop a new therapy to treat patients with severe asthma regardless of the underlying cause of inflammation, stated Robert Clarke, Ph.D., Chief Executive Officer of Kinaset Therapeutics.
  • Severe asthma affects about 10% of the entire asthma population, impacts quality of life and results in recurrent exacerbations that can lead to hospitalization.
  • Successful completion of this Phase 1b study will enable further investigations in patients with stable moderate to severe asthma and chronic obstructive pulmonary disease (COPD) with outcomes facilitating dose selection for subsequent Phase 2 clinical evaluation.

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Tuesday, September 14, 2021 - 2:10pm

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.

Key Points: 
  • Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
  • A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
  • Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.

Inspira Technologies Files a Patent Application for a Supportive Device to be Utilized with the ART Device

Wednesday, September 15, 2021 - 1:00pm

Ltd ("Inspira Technologies" or the "Company") (NASDAQ: IINN) (NASDAQ: IINNW), a specialty medical device company engaged in the research, development, manufacturing, and marketing of proprietary respiratory support technologies, announced today that it has submitted a patent application to the Israeli Patent Officefor a supportive device to be utilized with its ART device.

Key Points: 
  • Ltd ("Inspira Technologies" or the "Company") (NASDAQ: IINN) (NASDAQ: IINNW), a specialty medical device company engaged in the research, development, manufacturing, and marketing of proprietary respiratory support technologies, announced today that it has submitted a patent application to the Israeli Patent Officefor a supportive device to be utilized with its ART device.
  • The supportive device is aimed to allow for a safe treatment and mobilization of cannulated patients.
  • The Company chose to file the patent in the Israeli Patent Office since it is recognized as a leading International Search Authority.
  • Inspira Technologies is developingan early extracorporeal respiratory support system, the ART device, which functionsas an "artificial lung".

Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology Convergence 2021

Wednesday, September 15, 2021 - 12:00pm

BLACKSBURG, Va., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that it will present preclinical data of LABP-104, an oral, small-molecule LANCL2 agonist, in Systemic Lupus Erythematosus (SLE or Lupus) as an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2021. The meeting will be held virtually from November 3-10, 2021.

Key Points: 
  • platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that it will present preclinical data of LABP-104, an oral, small-molecule LANCL2 agonist, in Systemic Lupus Erythematosus (SLE or Lupus) as an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2021.
  • Landos expects to enter Phase 1 clinical testing of LABP-104 as an oral therapeutic candidate for lupus during the fourth quarter of 2021, further expanding the companys deep inflammation and immunology pipeline.
  • Landos Biopharma has 17 active development programs targeting these novel pathways at the interface of immunity and metabolism.
  • In addition, the forward-looking statements included in this press release represent the Companys views only as of the date hereof.

Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA

Wednesday, September 15, 2021 - 12:00pm

Pulmocides lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA

Key Points: 
  • Pulmocides lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
    London, UK; 15 September 2021 Pulmocide Ltd. (the Company), a late-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for patients with severe pulmonary diseases, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug, Fast Track and Qualified Infectious Disease Product designations for opelconazole (PC945) for the treatment of invasive pulmonary aspergillosis (IPA).
  • Fast Track designation is an FDA process designed to facilitate the development, and expedite the review of treatments to treat serious conditions and fill unmet medical needs.
  • Qualified Infectious Disease Product (QIDP) designation provides incentives to drug manufacturers to develop new treatments for serious fungal and antibiotic-resistant bacterial infections.
  • Pulmocides lead product is opelconazole (PC945), a novel antifungal therapy specifically designed for inhaled use to maximize the amount of drug in the lung and spare systemic exposure.